Response Genetics RGDXQ Stock
Response Genetics Price Chart
Response Genetics RGDXQ Financial and Trading Overview
| Response Genetics stock price | 0.0001 USD |
| Previous Close | 1.0E-6 USD |
| Open | 1.0E-6 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.0E-6 - 1.0E-6 USD |
| 52 Week Range | 1.0E-6 - 0.0001 USD |
| Volume | 77K USD |
| Avg. Volume | 0 USD |
| Market Cap | 116 USD |
| Beta (5Y Monthly) | 5.260563 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.39 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RGDXQ Valuation Measures
| Enterprise Value | 9.21M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.981224E-6 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 0.554 |
| Enterprise Value/EBITDA | -0.717 |
Trading Information
Response Genetics Stock Price History
| Beta (5Y Monthly) | 5.260563 |
| 52-Week Change | 0% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.0001 USD |
| 52 Week Low | 1.0E-6 USD |
| 50-Day Moving Average | 0.0001 USD |
| 200-Day Moving Average | 0.0001 USD |
RGDXQ Share Statistics
| Avg. Volume (3 month) | 0 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 38.8M |
| Float | N/A |
| Short Ratio | 0.31 |
| % Held by Insiders | 0% |
| % Held by Institutions | 0% |
| Shares Short | 78.1K |
| Short % of Float | 0.30% |
| Short % of Shares Outstanding | 0.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2014 |
| Most Recent Quarter (mrq) | March 31, 2015 |
| Next Fiscal Year End | December 31, 2015 |
Profitability
| Profit Margin | -85.54% |
| Operating Margin (ttm) | -82.15% |
| Gross Margin | 37.60% |
| EBITDA Margin | -77.26% |
Management Effectiveness
| Return on Assets (ttm) | -67.88% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 16.62M USD |
| Revenue Per Share (ttm) | 0.43 USD |
| Quarterly Revenue Growth (yoy) | -2.70% |
| Gross Profit (ttm) | 6.23M USD |
| EBITDA | -12837935 USD |
| Net Income Avi to Common (ttm) | -14213303 USD |
| Diluted EPS (ttm) | -0.39 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.73M USD |
| Total Cash Per Share (mrq) | 0.05 USD |
| Total Debt (mrq) | 10.94M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.795 |
| Book Value Per Share (mrq) | -0.127 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -13085395 USD |
| Levered Free Cash Flow (ttm) | -8107541 USD |
Profile of Response Genetics
| Country | United States |
| State | CA |
| City | Los Angeles |
| Address | 1640 Marengo Street |
| ZIP | 90033 |
| Phone | 323-224-3900 |
| Website | https://www.responsegenetics.com |
| Industry | Diagnostics & Research |
| Sector(s) | Healthcare |
| Full Time Employees | 96 |
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Q&A For Response Genetics Stock
What is a current RGDXQ stock price?
Response Genetics RGDXQ stock price today per share is 0.0001 USD.
How to purchase Response Genetics stock?
You can buy RGDXQ shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Response Genetics?
The stock symbol or ticker of Response Genetics is RGDXQ.
Which industry does the Response Genetics company belong to?
The Response Genetics industry is Diagnostics & Research.
How many shares does Response Genetics have in circulation?
The max supply of Response Genetics shares is 116.39M.
What is Response Genetics Price to Earnings Ratio (PE Ratio)?
Response Genetics PE Ratio is now.
What was Response Genetics earnings per share over the trailing 12 months (TTM)?
Response Genetics EPS is -0.39 USD over the trailing 12 months.
Which sector does the Response Genetics company belong to?
The Response Genetics sector is Healthcare.